Format

Send to

Choose Destination
Crit Rev Oncog. 2014;19(6):447-54.

Raf kinase inhibitory protein (RKIP) as a metastasis suppressor: regulation of signaling networks in cancer.

Author information

1
Ben May Department for Cancer Research, University of Chicago, Gordon Center for Integrative Sciences, Chicago, Illinois; and Committee on Cancer Biology, Biomedical Sciences Cluster, University of Chicago, Chicago, Illinois.
2
Ben May Department for Cancer Research, University of Chicago, Gordon Center for Integrative Sciences, Chicago, Illinois.

Abstract

Cancer is one of the deadliest diseases worldwide, accounting for about 8 million deaths a year. For solid tumors, cancer patients die as a result of the metastatic spread of the tumor to the rest of the body. Therefore, there is a clinical need for understanding the molecular and cellular basis of metastasis, identifying patients whose tumors are more likely to metastasize, and developing effective therapies against metastatic progression. Over the years, Raf kinase inhibitory protein (RKIP) has emerged as a natural suppressor of the metastatic process, constituting a tool for studying metastasis and its clinical outcomes. Here, we review RKIP's role as a metastasis suppressor and the signaling networks and genes regulated by RKIP in metastatic, triple-negative breast cancer. We also highlight the clinical implications and power of building gene signatures based on RKIP-regulated signaling modules in identifying cancer patients that are at higher risk for metastases. Finally, we highlight the potential of RKIP as a tool for developing new therapeutic strategies in cancer treatment.

PMID:
25597354
PMCID:
PMC4311870
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BegellHouse Publisher, Inc. Icon for PubMed Central
Loading ...
Support Center